Canaccord analyst William Plovanic lowered the firm’s price target on Boston Scientific (BSX) to $131 from $132 and keeps a Buy rating on the shares.The firm said they continue to be bullish on the Med-Tech sector heading into 2026. They point to strong underlying demand from an aging population, a focus on acute healthcare needs, the healthy pace of M&A, and a market that is receptive to IPOs as the foundation for our belief in our positive outlook in the upcoming year.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific’s WATCHMAN FLX Pro Registry: A New Frontier in Atrial Fibrillation Treatment
- 3 Best ETFs to Invest In, According to AI Analyst, 12/09/2025
- Boston Scientific’s Strong Growth Potential in EP Market Justifies Buy Rating
- Boston Scientific put volume heavy and directionally bearish
- Boston Scientific Approves 2026 Bonus Plan